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ABSTRACT 
Semelil (ANGIPARS™), an herbal formulation containing Melilotus officinalis extract, is a 
novel compound being developed for treatment of chronic wounds, particularly diabetic 
foot ulcers. The purpose of this study was to investigate toxicological, pharmacological, 
and pathomorphological effects of I.M. and I.P. administration of Semelil in animals. 
The acute toxicity parameters of Semelil diluted in normal saline (1:10 or 1:5) were 
determined after a single injection into BALB/c mice and Wistar rats in two steps. First, the 
LD50 was approximately assessed and then the precise lethal dose indices were estimated by 
the probit-analysis method. Specific single-dose effects of Semelil were monitored for 
clinical signs of toxicity, including general state of the animals, changes in their behavior, 
hematological and biochemical parameters for 14 days after drug administration. Then, 
subacute-chronic toxicity was evaluated in rats treated with Semelil for 3 months.  
In acute toxicity study, the calculated LD50 for drug diluted at 1:5 was in the range of 44-52 
ml/kg. The adverse effects at drug doses close to the LD50 included depressed mood, 
narcosis, and sleep. No adverse pharmacological or toxicological effects of the drug diluted 
at 1:10 and administered in the single-dose (25-50 ml/kg body wt.) or chronically (daily 
doses of 0.07 and 0.21 ml/kg body wt.) were noted. Thus, the animal studies demonstrated 
a favorable safety profile for the phytotherapeutic Semelil. 
_________________________________________________________________________ 
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INTRODUCTION 
Among patients with diabetes mellitus, up to 15% 
will experience a foot ulcer in their lifetime (1), 
and that is a major risk factor for future lower-
extremity amputation in diabetics (2-4). In spite of 
all therapeutic efforts to prevent amputation in 
diabetic patients in the last decade, the incidence 
of lower-extremity amputation is rising both in 
developed and developing countries (5,6). 
Therefore, new appropriate drugs to heal diabetic 
wound are essential. There are several recognized 
methods for treatment of sub-acute diabetic 
wounds. However, there is a need for alternative 
and complementary pharmacotherapy that 
provides accelerated healing and decrease the rate 
of recurrent ulcer complications and prevent 
major surgery and limb amputation. Herbal 
extracts are among medications with wound 
healing properties that can be applied more easily 
on wounds. Previous studies have reported a 
potential usefulness of internal and external 
administration of Melilotus officinalis (Yellow 
Sweet Clover) extract for micro-circulation 
improvement in leg chronic venous insufficiency 
and hydrocortisone-like anti-inflammatory effects 
(7,8). The activity of extract of Herba Meliloti in 
combination with Dipteryx odorata and Ginkgo 
biloba was very significant for treatment of 
lymphedema of lower limbs (7-9). According to 
these known effects of Melilotus officinalis, a 
novel herbal-based compound was supposed to 
cure chronic wounds, particularly diabetic foot 
ulcers and was formulated. Advantageously, this 
drug “Semelil” have provided full healing with 
accelerated wound closure. Surprisingly, it also 
improved the quality of tissue in the healing 
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wound with very noticeable hair growth on the 
scar tissue that ensured a lower rate of ulcer 
recurrence in the future.  
The aim of this study was to evaluate safety of 
Semelil as a new candidate drug for wound 
healing in toxicity tests in rodent.  
 
MATERIALS AND METHODS 
Semelil herbal extract (ANGIPARS™) was 
prepared and delivered by ParsRoos Co. (Tehran, 
Iran). Total protein, creatinine, urea, total 
bilirubin, of lactate dehydrogenase and alkaline 
phosphatase activity were determined by a set of 
reagents of Diakom-Sinteco (Russia). The 
triglyceride and cholesterol levels were measured 
by a set of reagents of DiaSys Diagnostic Systems 
GmbH. (Germany). The activity of alanine 
aminoteransferase was determined using a set of 
reagents of Corway (Poland). All other 
biochemical parameters and enzyme activities 
were determined using a biochemical 
semiautomatic analyzer FP-901 (Labsystems, 
Finland). The blood elements were counted using 
automatic cell counter Picoskel (Hungary). The 
glucose level was measured by a set of reagents of 
the Labsystems Co. (Helsinki, Finland) 
 
Drug solution preparation 
ANGIPARS™ was freshly diluted in sterile saline 
(0.9% sodium chloride) at 1:5 or 1:10 ratios and 
then different portions of the solution were 
administered to animals.  
 
Animals 
BALB/c mice and Wistar rats were employed for 
administration of the preparation intramuscularly 
(in mice) and intraperitoneally (in mice and rats). 
The protocol of the study was approved by the 
Center Animals Ethics Committee. 
The animals, male and female BALB/c mice (18-
20g) and Wistar rats (120-180g) that had a 
veterinary and health certificates were taken from 
Laboratory animal farm Stolbovaya (RAMS, 
Russia) and the animals were kept in type T-3 
(mice) and T-4 (rats) cages (Velaz, Prague, Czech 
Republic), 7-8 animals in each, at 20-22ºC and 
60-65% humidity under a 12h light/dark cycle and 
had free access to food and tap water. 
 
Single-dose toxicity evaluation 
The toxicity of diluted Semelil was determined 
after a single injection into animals (male and 
female of 128 mice and 48 rats) in two steps. 
First, the LD50 of Semelil intramuscularly (in 
mice) and intraperitoneally (in mice and rats) 
were approximately established with acute dose 
schedule used as recommended by Deichmann 
and LeBlanc (10). The precise fatal toxicity 
indices of LD16, LD50 and LD84 were determined 
by the probit-analysis method of Litchfield and 
Wilcoxon (12). Then, single sub-acute doses of 
the drug were injected by I.M. and I.P. routs and 
the animals were observed for viability and 
clinical signs of toxicity on the day of dosing and 
then daily for 14 days (11). 
 
Sub-chronic toxicity evaluation  
Preliminary chronic safety studies with Semelil 
were performed on 90 male and female Wistar 
rats at sub-acute doses for 3 months. The rats 
were divided into 3 groups, 30 animals in each 
(15 male and 15 female) and Semelil was 
administered at doses of 0.07 ml/kg and 0.21 
ml/kg once a day intramuscularly to the 2nd and 
3rd groups, respectively. The first group received 
sterile solution of sodium chloride 0.9% as 
control. During the experiment, general state 
including the dynamics of body weight changes, 
appetite, motor activity, hair condition and 
behavior of the animals were recorded (13,14). 
Blood samples (2.0-2.5 ml) were taken from 
caudal vein of each animal for hematological and 
biochemical analyses at the start of the study and 
1 and 3 months after the first administration of 
drug or saline.  
At the end of the chronic experiment, the animals’ 
euthanasia was performed by diethyl ether 
narcosis and pathomorphology of the internal 
organs and tissues of the animals were examined. 
The autopsy of animals was performed 
immediately after death according to the 
pathoanatomic scheme, which reduced the 
possibility of autolysis. 
 
Statistical Analyses 
All measured variables were demonstrated as 
mean and SD. Statistical analyses were performed 
by using SPSS software, version 11.5 and Stata 
version 8. The probability levels of significance 
were based on Student’s t-test or non-parametric 
test, considering the normality of tested variable. 
Statistically significance level was set at p<0.05. 
 
RESULTS AND DISCUSSION 
 
Single dose toxicity evaluation  
The results of acute intoxication study after 
single-dose of the drug introduced to BALB/c 
mice and Wistar rats and calculated I.M./I.P. fatal 
toxicity indices are presented in Table 1. The 
single i.m. injection of Semelil diluted in sterile 
saline at 1: 10 ratio at the doses of 0.5-1 ml/mouse 
(25-50 ml/kg) did not cause any toxicity and 
death. Increasing the dose to 1.5-2 ml/mouse (75-
100 ml/kg) remarkably decreased motor activity 
in mice and caused some deaths. The 
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Table 1. Acute toxicity parameters of Semelil and ethanol 96% diluted (1:5) in solution of sodium chloride 0.9% 
following I.M. or I.P. administration to mice and rats. 
Fatal toxicity indices, ml/kg 
Females Males  
LD84 LD50±SD LD16 LD84 LD50±SD LD16 Routes of adminstration 
                                                 BALB/c mice, Semelil 
78.3 48.5±4.6 29.2 81.6 51.8±8.6 35.5                   Intramuscular 
74.7 44.9±5.3 25.6 77.5 47.7±4.9 28.4                   Intraperitoneal 
                                                              BALB/c mice, Ethanol 96% 
42.7 35.2 28.3 44.8 37.3±2.1 30.4                   Intraperitoneal 
                                                        Wistar rats, Semelil 
71.8 42.1±5.7 22.7 74.4 44.6±6.3 25.3                    Intraperitoneal 
  The data are presented as mean ± standard deviation (SD); LD= lethal dose. 
 
 
 
Table 2. Hematological parameters in male rats (3-month study) after Semelil I.M. administration at the dose of 0.07 
and 0.21 ml/kg once a day. The control group received 0.9% sodium chloride. 
Semelil 
0.21 ml/kg 
Semelil 
0.07 ml/kg Control Observation period 
Erythrocytes, 1012/l 
7.4 ± 1.2 7.7 ± 1.2 7.5 ± 1.2 Before introduction 
7.5 ± 1.6 7.3 ± 1.6 7.4 ± 1.6 1 month after introduction 
7.4 ± 1.2 7.5 ± 1.2 7.6 ± 1.2 3 months after introduction 
Leukocytes, 109/l 
11.9 ± 1.6 12.1 ± 1.6 11.7 ± 2 Before introduction 
12.1 ± 1.2 12.6 ± 1.2 12.03 ± 2.8 1 month after introduction 
12.2 ± 2 12.3 ± 1.6 12.1 ± 2 3 months after introduction 
Thrombocytes, 109/l 
685 ± 124 705 ± 88 692 ± 116 Before introduction 
699 ± 104 693 ± 96 701 ± 124 1 month after introduction 
707± 128 702 ± 124 697 ± 92 3 months after introduction 
Hemoglobin, g/l 
114 ± 12 111 ± 16 113 ± 12 Before introduction 
115 ± 20 116 ± 16 111 ± 12 1 month after introduction 
116 ± 16 114 ± 12 115± 16 3 months after introduction 
 Data are means ± standard deviation; All significance levels between groups were p>0.05. 
 
 
intramuscular injection of Semelil diluted at 1:5 
ratios was painful and caused profound depression 
and some deaths. In acute toxicity study, the 
calculated LD50 for drug diluted at 1:5 was in the 
range of 44-52 ml/kg. There was no significant 
difference (p > 0.05) between acute toxicity data 
obtained in experiments using I.M. and I.P. routes 
of drug administration (Table 1). 
I.M. and I.P. injection of Semelil to BALB/c 
mice, in doses close to LD50, was accompanied by 
clear depression, narcosis and sleep in animals. In 
the autopsy of animals plethora of the internal 
organs was observed. The clinical picture of the 
intoxication of Wistar rats with equivalent doses 
of Semelil at 1:5 dilution was similar to that of 
mice.  
No specific and sex-related differences in the 
sensitivity of the animal species to the toxic 
effects of Semelil were detected when it was 
administered to BALB/c mice and Wistar rats 
intraperitoneally. 
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Table 3. Hematological parameters in female rats (3-month study) after Semelil I.M. administration at the dose of 
0.07 and 0.21 ml/kg once a day. The control group received 0.9% sodium chloride. 
Semelil 
0.21 ml/kg 
Semelil 
0.07 ml/kg Control Observation period 
Erythrocytes, 1012/l 
7.4 ± 1.2 7.5 ± 1.6 7.4 ± 1.2 Before introduction 
7.3 ± 1.6 7.7 ± 1.2 7.5 ± 1.6 1 month after introduction 
7.5 ± 1.2 7.3 ± 1.2 7.6 ± 1.2 3 months after introduction 
Leukocytes, 109/l 
11.9 ± 1.6 12.5 ± 2.4 11.8 ± 1.6 Before introduction 
12.3 ± 1.2 12.3 ± 1.2 12.0 ± 1.2 1 month after introduction 
11.6 ± 1.2 11.9 ± 3.6 12.1 ± 0.8 3 months after introduction 
Thrombocytes, 109/l 
701 ± 92 692 ± 116 703 ± 116 Before introduction 
705 ± 104 699 ± 104 708 ± 124 1 month after introduction 
697 ± 116 705 ± 124 697 ± 104 3 months after introduction 
Hemoglobin, g/l 
116 ± 16 114 ± 12 113 ± 16 Before introduction 
118 ± 12 116 ± 12 112 ± 32 1 month after introduction 
117 ± 12 118 ± 16 115 ± 16 3 months after introduction 
Data are means ± standard deviation; All significance levels between groups were p>0.05. 
 
 
 
Table 4. Hepatic enzyme activity of male rats (3-month study) after Semelil I.M. administration at the dose of 0.07 
and 0.21 ml/kg once a day. The control group received 0.9% sodium chloride. 
Semelil 
0.21 ml/kg Semelil 0.07 ml/kg Control Observation period 
Alkaline phosphatase, unit/l 
516.8 ± 128 499.4 ± 154 504.9 ± 177 Before introduction 
514.9 ± 131 486.2 ± 175 480.8 ± 108 1 month after introduction 
494.4 ± 136 487.7 ± 145 469.7 ± 159 3 months after introduction 
Alanine aminotransferase, unit/l 
61.84 ± 16 60.81 ± 22 65.82 ± 23 Before introduction 
66.29 ± 17 64.91 ± 18 67.21 ± 25 1 month after introduction 
62.71 ± 13 62.69 ± 20 60.85 ± 18 3 months after introduction 
Aspartate aminotransferase, unit/l 
89.32 ± 26 91.38 ± 36 90.87 ± 33 Before introduction 
85.73 ± 36 84.44 ± 28 81.11 ± 32 1 month after introduction 
84.31 ± 35 86.66 ± 26 87.92 ± 26 3 months after introduction 
Lactate dehydrogenase, unit/l 
798.36 ± 209 809.84 ± 165 747.38 ± 240 Before introduction 
771.44 ± 154 772.73 ± 190 820.26 ± 275 1 month after introduction 
797.36 ± 138 794.77 ± 246 738.63 ± 259 3 months after introduction 
Data are means ± standard deviation; All significance levels between groups were p>0.05. 
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Table 5. Hepatic enzyme activity of female rats (3-month study) after Semelil I.M. administration at the dose of 0.07 
and 0.21 ml/kg once a day . The control group received 0.9% sodium chloride. 
Semelil 
0.21 ml/kg 
Semelil 
0.07 ml/kg Control Observation period 
Alkaline phosphatase, unit/l 
508.7 ± 192 501.4 ± 184 494.9 ± 151 Before introduction 
489.4 ± 156 558.1 ± 154 509.2 ± 154 1 month after introduction 
491.9 ± 156 509.8 ± 153 500.3 ± 196 3 month after introduction 
Alanine aminotransferase, unit/l 
62.08 ± 23 68.82 ± 19 62.84 ± 21 Before introduction 
68.78 ± 17 64.29 ± 23 59.37 ± 21 1 month after introduction 
59.89 ± 21 62.04 ± 21 61.86 ± 25 3 months after introduction 
Aspartate aminotransferase, unit/l 
99.46 ± 30 100.88 ± 34 92.61 ± 39 Before introduction 
97.82 ± 33 102.76 ± 33 96.24 ± 25 1 month after introduction 
94.29 ± 36 108.27 ± 33 92.88 ± 37 3 months after introduction 
Lactate dehydrogenase, unit/l 
902.35 ± 209 879.84 ± 205 857.28 ± 193 Before introduction 
863.76 ± 239 887.64 ± 186 801.30 ± 166 1 month after introduction 
875.24 ± 207 861.82 ± 153 798.32 ± 169 1 months after introduction 
Data are means ± standard deviation; All significance levels between groups were p>0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The dynamics of body weight changes in female rats (3-month study) following Semelil I.M. 
administration at the dose of 0.07 and 0.21 ml/kg once a day. The control group received 0.9% sodium chloride. 
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Table 6.Biochemical parameters in male rats (3-month study) after Semelil I.M. administration at the dose of 0.07 
and 0.21 ml/kg once a day . The control group received 0.9% sodium chloride. 
Semelil 
0.21 ml/kg 
Semelil 
0.07 ml/kg Control Observation period 
Total protein, g/l 
62.8 ± 8 60.2 ± 14 61.8 ± 11.5 Before introduction 
66.7 ± 6.9 66.0 ± 10 63.7 ± 9.5 1 month after introduction 
64.4 ± 10.8 62.5 ± 13.7 61.9 ± 13.5 3 months after introduction 
Bilirubin, µmol/l 
7.69 ± 1.5 7.89 ± 2.5 7.29 ± 2 Before introduction 
7.85 ± 2 7.80 ± 2 7.39 ± 1.8 1 month after introduction 
7.69 ± 1.8 7.78 ± 1.5 7.58 ± 1.5 3 months after introduction 
Urea, mmol/l 
10.28 ± 3.5 11.81 ± 3.5 10.48 ± 2.5 Before introduction 
10.36 ± 2.5 10.47 ± 2.2 11.16 ± 1.7 1 month after introduction 
11.27 ± 2.6 10.72 ± 2.1 10.35 ± 2.6 3 months after introduction 
Creatinine, µmol/l 
62.13 ± 21 61.75 ± 21 58.82± 22 Before introduction 
63.52 ± 16.6 66.12 ± 22.6 64.66 ± 26 1 month after introduction 
69.69 ± 20.7 60.09 ± 16.6 63.02 ± 21 3 months after introduction 
Glucose, µmol/l 
7.34 ± 1.0 7.58 ± 1.4 7.43 ± 1.3 Before introduction 
7.52 ± 1.2 7.33 ± 1.1 7.44 ± 1.1 1 month after introduction 
7.44 ± 0.9 7.47 ± 1.2 7.45 ± 0.8 3 months after introduction 
Total cholesterol, mmol/l 
1.28 ± 0.76 1.14 ± 0.36 1.16 ± 0.32 Before introduction 
1.36 ± 0.56 1.04 ± 0.32 1.18 ± 0.28 1 month after introduction 
1.27 ± 0.32 1.16 ± 0.4 1.32 ± 0.36 3 months after introduction 
Triglycerides, mmol/l 
0.70 ± 0.28 0.71 ± 0.32 0.67 ± 0.2 Before introduction 
0.67 ± 0.32 0.75 ± 0.48 0.62 ± 0.2 1 month after introduction 
0.79 ± 0.44 0.69 ± 0.24 0.55 ± 0.32 3 months after introduction 
Data are means ± standard deviation; All significance levels between groups were p>0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The dynamics of body weight changes in male rats (3-month study) following Semelil I.M. 
administration at the dose of 0.07 and 0.21 ml/kg once a day. The control group received 0.9% sodium chloride. 
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Table 7. Biochemical parameters in female rats (3-month study) after Semelil I.M. administration at the dose of 0.07 
and 0.21 ml/kg once a day . The control group received 0.9% sodium chloride. 
Semelil 
0.21 ml/kg 
Semelil 
0.07 ml/kg Control Observation period 
Total protein, g/l 
66.4 ± 9.4 62.6 ± 10.7 62.7 ± 9.5 Before introduction 
66.8 ± 9.5 63.09 ± 11.3 63.1 ± 10.3 1 month after introduction 
64.5 ± 8.9 62.6 ± 9.6 62.9± 9.7 3 months after introduction 
Bilirubin, µmol/l 
7.59 ± 1.8 7.88 ± 1.9 7.61 ± 2.2 Before introduction 
7.48 ± 1.7 7.62 ± 1.9 7.28 ± 1.9 1 month after introduction 
7.69 ± 1.9 7.94 ± 2.1 7.86 ± 2 3 months after introduction 
Urea, mmol/l 
10.87 ± 3 11.06 ± 2.7 10.82 ± 2.1 Before introduction 
10.29 ± 2.3 10.28 ± 2.5 10.38 ± 2.3 1 month after introduction 
10.20 ± 2 10.36 ± 2.2 10.28 ± 2 3 months after introduction 
Creatinine, µmol/l 
62.18 ± 17.9 64.85 ± 23.2 59.62 ± 18.5 Before introduction 
65.23 ± 17.3 48.78 ± 19.4 62.58 ± 17.3 1 month after introduction 
61.41 ± 20.1 66.82 ± 18.5 60.29 ± 17.4 3 months after introduction 
Glucose, µmol/l 
7.59 ± 1.4 7.39 ± 1.3 7.38 ± 1.2 Before introduction 
7.48 ± 1.2 7.58 ± 1.5 7.36 ± 1.1 1 month after introduction 
7.69 ± 1.2 7.49 ± 1.0 7.39 ± 1.5 3 months after introduction 
Total cholesterol, mmol/l 
1.28 ± 0.32 1.09 ± 0.36 1.19 ± 0.32 Before introduction 
1.28 ± 0.36 1.28 ± 0.32 1.29 ± 0.32 1 month after introduction 
1.26 ± 0.36 1.19 ± 0.32 1.26 ± 0.36 3 months after introduction 
Triglycerides, mmol/l 
0.71 ± 0.32 0.69 ± 0.28 0.70 ± 0.28 Before introduction 
0.78 ± 0.36 0.72 ± 0.36 0.78 ± 0.32 1 month after introduction 
0.79 ± 0.36 0.76 ± 0.36 0.72 ± 0.36 3 months after introduction 
  Data are means ± standard deviation; All significance levels between groups were p>0.05. 
 
Sub-chronic toxicity evaluation  
Daily I.M. injections of Semelil at the doses of 
0.07 and 0.21 ml/kg body weight had no effect on 
general state and behavior of rats. We did not 
detect any significant changes in hematological 
and biochemical parameters including total serum 
proteins, bilirubin, glucose content, triglycerides, 
cholesterol, and blood urea and creatinine, in test 
animal groups compared to control group after 1 
and 3 months in rats. The activities of hepatic 
enzymes of test and control groups did not show 
any difference and corresponded to their 
physiological ranges, which are typical for these 
animals (Tables 1-7).  
Mean body weights of rats in experimental 
groups, whether they received the preparation in 
doses of 0.07 or 0.21 ml/kg during all chronic 
toxicity experiment, were not significantly 
different (p > 0.05) from those of control animals 
(Fig. 1,2).  
 
Pathomorphological examination of animals after 
chronic experiment 
At necropsy, macroscopic evaluation of the 
animals together with microscopic data showed 
that both test and control groups were practically 
healthy. No toxic or toxico-allergic effects of 
Semelil were revealed in the test groups (2nd and 
3rd) of rats. No pathological changes of the 
internal organs and no local-irritating effects of 
the preparation were discovered in both test 
groups during the study period Our experiments 
showed that Semelil is a low-toxic substance after 
I.M. and I.P. administration to BALB/c mice and 
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Wistar rats. Since there were no drug adverse 
effects and the calculated LD50 was in the range of 
44-52 ml/kg in the acute dose study, it can be 
concluded that Semelil was well tolerated in rats 
both at I.M. administered doses of 0.07 and 0.21 
ml/kg, which were used in the sub-acute chronic 
toxicity study. 
Considering the profound effects of 
intraperitoneal and intramuscular injections of 
Semelil at dose levels close to the LD50 such as 
depression, narcosis and sleep, and their similarity 
to intoxication by ethanol (Table 1), which was 
used for the preparation of the drug, it can be 
assumed that these effects were directly related to 
this solvent.  
The data indicated the stability of protein-
productive function of liver, hepatic enzyme 
activity, carbohydrate metabolism, pancreas 
function, lipid metabolism, excretory kidney 
function of animals during the study period 
because we did not observe significant changes in 
recorded hematological and biochemical 
parameters in test groups compared to control 
group.  
 
CONCLUSION 
Results of the present study gave an evidence of 
good tolerance of Semelil and the absence of 
undesirable effects on the functional state of the 
vital organs of the experimental animals in sub-
acute and chronic test. Since antioxidants are 
believed to be useful in the management of 
diabetes and its complications (15) and regarding 
antioxidant potential of Semelil the next step of 
trials can be focused on diabetes.   
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